Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Single Ascending Dose (Part 1) and Single or Multi-Dose Expansion (Part 2) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

NCT07428473 is registered in ClinicalTrials.gov with Monash University as lead sponsor.

NCT NCT07428473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07428473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Single Ascending Dose (Part 1) and Single or Multi-Dose Expansion (Part 2) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
Lead sponsor
Monash University
Phase
Phase 1
Overall status
Recruiting
Start date
June 30, 2026
Completion date
December 30, 2028
Enrollment
64 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

elevated ldl-c and high cholesterol